SCHEMBL2403057

SCHEMBL2403057

NC(=O)Cn1c(=O)sc2cc([N+](=O)[O-])ccc21

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDYL2 Q8N8U2 4/20 0.64
CDYL Q9Y232 4/20 0.64
CBX7 O95931 2/20 0.59
CDY1; CDY1B Q9Y6F8 2/20 0.59
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 2/20 0.42
RAB9A P51151 1/20 0.40
PLA2G2A P14555 1/20 0.40
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032915 0.81 CYP1A2 (0.60) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
Hydrochloric Acid SCHEMBL10546042 0.81 CDYL2 (0.57) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL2407440 0.78 SIGMAR1 (0.50) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL2360782 0.78 NPY5R (0.47) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL15712481 0.77 CDYL2 (0.53) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL15712229 0.76 KDM4E (0.61) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL2332474 0.74 L3MBTL1 (0.60) KMT2APOLBSMN1; SMN2ALDH1A1TSHR
SCHEMBL10933312 0.74 CDYL2 (0.49) CDYL2CDYLCBX7CDY1; CDY1BKMT2A
SCHEMBL24993891 0.74 SIRT2 (0.52) KMT2ACYP1A2PLA2G2APOLBALDH1A1
SCHEMBL15712477 0.73 CDYL2 (0.49) CDYL2CDYLCBX7CDY1; CDY1BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
US-10806717-B2 Methods and compositions for improving cognitive function THE JOHNS HOPKINS UNIVERSITY (US) 2020-10-20 US disclosed
US-10624875-B2 Methods and compositions for treating schizophrenia THE JOHNS HOPKINS UNIVERSITY (US) 2020-04-21 US disclosed
EP-3610890-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA The Johns Hopkins University (US) 2020-02-19 EP disclosed
US-10154988-B2 Methods and compositions for treating schizophrenia THE JOHNS HOPKINS UNIVERSITY (US) 2018-12-18 US disclosed
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2012-08-23 US disclosed
WO-2012109491-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-16 WO disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders UCB PHARMA, S.A. (BE) 2010-09-02 US disclosed
EP-2152262-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB Pharma, S.A. (BE) 2010-02-17 EP disclosed
WO-2008132142-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB PHARMA S.A. (BE) 2008-11-06 WO disclosed
WO-2008132139-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB PHARMA S.A. (BE) 2008-11-06 WO disclosed
EP-0009331-B1 IMIDES DERIVED FROM 2-OXO-3-BENZOTHIAZOLINE-ACETIC ACID AND BUTYRIC ACID, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND AS PLANT GROWTH REGULANTS MONSANTO COMPANY (US) 1983-07-20 EP disclosed
EP-0009331-A1 Imides derived from 2-oxo-3-benzothiazoline-acetic acid and butyric acid, process for their preparation and their use as herbicides and as plant growth regulants MONSANTO COMPANY (US) 1980-04-02 EP disclosed
US-4185990-A HERBICIDES AND PLANT GROWTH REGULATORS MONSANTO COMPANY (US) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10806717-B2 Methods and compositions for improving cognitive function GRIN2A, CHRNA2, SYNGR2 CDYL2 339/4885CDYL 1611/4885CBX7 744/4885
US-10154988-B2 Methods and compositions for treating schizophrenia RAB2A, SYNGR2, GRIN2A CDYL2 971/4885CDYL 2385/4885CBX7 2821/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 CDYL2 339/4885CDYL 1611/4885CBX7 744/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A CDYL2 1832/4885CDYL 3482/4885CBX7 4340/4885
US-10624875-B2 Methods and compositions for treating schizophrenia RAB2A, SYNGR2, GRIN2A CDYL2 478/4885CDYL 1285/4885CBX7 2312/4885
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders CNR2, CNR1, SLC18A2 CDYL2 2678/4885CDYL 2832/4885CBX7 553/4885
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, GRIN2D, SLC18A2 CDYL2 2505/4885CDYL 4453/4885CBX7 4400/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 CDYL2 339/4885CDYL 1611/4885CBX7 744/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE CDYL2 3071/4885CDYL 4362/4885CBX7 4694/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE CDYL2 3071/4885CDYL 4362/4885CBX7 4694/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 CDYL2 2361/4885CDYL 4273/4885CBX7 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.